Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432574 · ClinicalTrials.gov registry record · Phase 2
Study of Gardasil in Mid-Adult Males (MAM)
A Phase 2 study of Human Papillomavirus, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT01432574 is a Phase 2 study of Human Papillomavirus that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 150 participants, below the 26,070-participant average among 12 other Human Papillomavirus trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01432574, a Phase 2 study of Human Papillomavirus, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test the effectiveness of the research study vaccine, Gardasil, in men ages 27-45 who have completed 4 years of observation in The Human Papillomavirus \[HPV\] infection in men (HIM) Study.
Conditions Studied
Interventions
- BIOLOGICAL Gardasil
Study Locations (2)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Other
- National Institute of Public Health, Mexico - Cuernavaca
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2013-02-19 |
| Est. Completion | 2020-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01432574
The ClinicalTrials.gov registry entry for NCT01432574 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,070-participant average among 12 other Human Papillomavirus trials with a reported enrollment target (99% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papillomavirus appearing as the primary indexed condition, and to 1 intervention - of which Gardasil is the first listed.
NCT01432574 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Other.
Frequently Asked Questions
What is clinical trial NCT01432574 about?
NCT01432574 is a clinical study titled "Study of Gardasil in Mid-Adult Males (MAM)". The purpose of this study is to test the effectiveness of the research study vaccine, Gardasil, in men ages 27-45 who have completed 4 years of observation in The Human Papillomavirus \[HPV\] infection in men (HIM) Study.
What is the current status of trial NCT01432574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2013-02-19. Estimated completion is 2020-11-03.
What conditions does trial NCT01432574 study?
This clinical trial studies the following conditions: Human Papillomavirus.
What interventions are being tested in trial NCT01432574?
The interventions under investigation include: Gardasil (BIOLOGICAL).
Who is sponsoring clinical trial NCT01432574?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01432574 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Provider Recommendation and HPV Vaccination
RECRUITING · NA
-
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
RECRUITING
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
RECRUITING
-
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.